Incyte Ingenuity Award

Supporting the GVHD community

icon

The application process for the 2020 Incyte Ingenuity Award program is now closed.

New applications for the Incyte Ingenuity Award will no longer be accepted at this time.

 

Introducing the 2020
Incyte Ingenuity Award!

 

The Incyte Ingenuity Award aims to support the US graft-versus-host disease (GVHD) community by funding one innovative initiative every year for up to $100,000. The selected initiative will address a critical unmet need for people impacted by GVHD.

GVHD is a life-threatening condition that occurs when donor immune cells attack the recipient's organs and tissues after an allogeneic stem cell transplant. There are two major forms of GVHD, acute and chronic, that can affect multiple organ systems, including the skin, digestive tract, and the liver. Both acute and chronic GVHD are associated with significant morbidity and mortality.

Incyte is deeply dedicated to improving the lives of patients with serious diseases, including GVHD. As a part of this commitment, the company launched the Incyte Ingenuity Award to help address challenges faced by patients with GVHD, their caregivers, and healthcare providers, as well as foster collaboration within the GVHD community to address specific unmet needs.

icon

The application process for the 2020 Incyte Ingenuity Award program is now closed.

New applications for the Incyte Ingenuity Award will no longer be accepted at this time.

Eligibility

Eligibility Information

The following groups and individuals are eligible to apply for the Incyte Ingenuity Award:

Image of hands holding heart

Non-profit 501(c)(3), patient, policy, and caregiver organizations

Image of caduceus

Healthcare providers and mid-level/junior faculty of healthcare organizations*

Image of two people

Individuals working or collaborating with these organizations and institutions

Programs must be independent of any ongoing activities, with the exception of considerably expanding an existing program. To be eligible, you and your organization must be US based (including Washington D.C. and Puerto Rico).

*Individuals submitting an application must submit in the name of their institution, not as individuals.

Applications will be disqualified if:

  • Focus is on a particular therapeutic agent, translational research, or clinical research that is interventional in nature.
  • Organization is improperly identified as a 501(c)(3) organization.
  • Application is submitted by a healthcare professional as an individual (individuals will need to partner with a not-for-profit or other organization to be considered).
  • Defined scope does not serve or plan to address unmet needs of the GVHD community.
  • Request in funding exceeds 25 percent of an organization’s overall funding.
  • Application is submitted by an employee of Incyte, VOZ Advisors, and/or other vendors, or members of the immediate family of any such persons.
  • Program is duplicated, with multiple copies of an application submitted by the same organization.
  • Program exceeds the maximum application limit per organization (more than five).
  • Program is based on an existing initiative, with no evidence of ingenuity.

Incyte reserves the right to modify the eligibility requirements at any time.

Judges

Meet the Judges

The Incyte Ingenuity Award will be reviewed by an independent judging panel. This year’s panel includes:

Image of Shrina Duggal

Shrina Duggal, PharmD, BCOP

Dr. Shrina Duggal, PharmD, BCOP, is a clinical pharmacy specialist in hematology/oncology/BMT at the University of Pittsburgh Medical Center Hillman Cancer Center. She has been working as a clinical pharmacy specialist at UPMC Hillman Cancer Center since 2007 and has experience in both the inpatient and outpatient settings managing patients with hematological malignancies and solid tumors and most recently in the management of patients receiving various immunotherapy agents. Dr. Duggal acts as faculty mentor and adjunct faculty member at West Virginia University School of Pharmacy and holds the position of adjunct faculty member at the University of Pittsburgh School of Pharmacy. She has lectured and taught extensively across the country and holds multiple preceptorships in experiential learning, pharmacy practice, and hematology/oncology/SCT specialty residencies. Dr. Duggal is a member of the Hematology Oncology Pharmacists Association, American College of Clinical Pharmacy, and American Society for Transplantation and Cellular Therapy.

More
Less
Image of Gerald Cowden

Gerald W. Cowden, JD

Gerald W. Cowden is a practicing attorney. He has been representing entrepreneurs, high-growth companies, and financial investors for more than 40 years. Mr. Cowden received his BA at Washington and Jefferson College and his JD at the University of Akron School of Law. In addition to his professional career as a Partner at Cowden & Humphrey, he is also a cofounder of a patient advocacy group, the Meredith A. Cowden Foundation. Mr. Cowden is currently or has been a member or a trustee of numerous prominent state and national business associations or committees including the Corporate Sections of the Cleveland and Akron Bar Associations, the Corporation Law Committee and Taxation Law Committee of the Ohio Bar Association, and the American Bar Association. In addition, he has served as a judge in the Ernst & Young Entrepreneur of the Year Program and on many corporate and advisory boards for both clients and nonclients. In 2007, in conjunction with his daughter Meredith and his wife Marti, he cofounded the Meredith A. Cowden Foundation (www.cowdenfoundation.org). The Foundation’s mission is to raise awareness of the impact of leukemia and graft-versus-host disease (GVHD), to fund research for GVHD, and to provide financial support for nonmedical expenses associated with blood cancers. Every year the Cowden Foundation holds the GVHD National Symposium where research physicians present the latest and greatest methods to help patients living with GVHD. In 2019, the Cowden Foundation received the Lifeblood Award from the Leukemia & Lymphoma Society. Most recently, in February 2020, Mr. Cowden received the Public Service Award from the American Society of Transplantation and Cellular Therapy to honor the work of the Cowden Foundation. Mr. Cowden lives in Akron with his wife of 49 years and has two daughters, Margaux and Meredith.

More
Less
Image of Navneet Majhail

Navneet Majhail, MBBS, MD, MS

Dr. Navneet Majhail is the Director of the Blood & Marrow Transplant Program at the Taussig Cancer Institute, Cleveland Clinic, and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio. He has also previously served as President of the American Society for Transplantation and Cellular Therapy. Dr. Majhail specializes in the care of adult patients receiving blood and marrow transplantation. His research focuses on transplant outcomes, health services and health policy issues in blood and marrow transplantation, and quality of life and late effects in transplant survivors, including patients with graft-versus-host disease. His research has been funded by the Patient Centered Outcomes Research Institute and the National Institutes of Health.  

More
Less
copy

Incyte will not provide any advice or input during the judging process, and all decisions made by the judging panel are final. These judges will receive compensation for their services from Incyte, based on fair market value.

Judging Criteria

Judging Criteria

Our independent judging panel will consider the following criteria when evaluating each award application:

Does the applicant meet the eligibility requirements?

Does the application contain all of the necessary details and supporting documents?

Does the proposal address an unmet need within the GVHD community?

Can the proposal be completed within the one-year time frame?

Does the proposal demonstrate a clear purpose and rationale?

Does the proposal include a realistic and appropriate budget?

Does the proposal have clear and measurable outcomes? Does it follow the SMART (specific, measurable, achievable, realistic, timely) methodology for setting goals?

Incyte reserves the right to change the judging criteria at any time.

Program Rules

Program Guidance

icon

The application process for the 2020 Incyte Ingenuity Award program is now closed.

New applications for the Incyte Ingenuity Award will no longer be accepted at this time.

The application process will occur in two rounds:

  Round one

Fill out an online application, including the following information:

  • Name of applicant, primary contact information, agreement to eligibility criteria, and all terms (e.g., confirmation of 501(c)(3) status, new initiative), date of submission
  • Identification of any collaboration and team overview, including credentials/capabilities
  • Project summary, exhibiting an innovative approach to address a specific unmet need
  • Identification of any organizational challenges in execution
  • Identification of any specific capacity-building needs to launch initiative
  • Realistic high-level timeline to execute initiative within one year of selection
  • Measurable elements and anticipated outcomes as a way to demonstrate impact in the GVHD community

  Round two

The top three entries will be selected by the independent judging panel to submit a detailed proposal of their initiative. The official proposal must include:

  • A clear description of goals and key milestones that outline how the critical unmet need will be addressed
  • A detailed outline of specific activities involved to launch initiative and timeline
  • An itemized budget with narrative justification
  • Identification of specific outcomes
  • Methodology to evaluate initiative’s short-term and long-term reporting plans